Docoh
Loading...

CCEL Cryo Cell International

Founded in 1989, Cryo-Cell International Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its family bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s mission is to provide clients withstate-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their baby’s cord blood and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 13485:2003–certified by TÜV, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.

Company profile

Ticker
CCEL
Exchange
CEO
Mark L. Portnoy / David I. Portnoy
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
223023093

CCEL stock data

(
)

Calendar

14 Apr 21
13 Jun 21
30 Nov 21
Quarter (USD)
Feb 21 Nov 20 Aug 20 May 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Nov 20 Nov 19 Nov 18 Nov 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 May 21 Portnoy David Common Stock Buy Aquire P Yes No 8.65 946 8.18K 98,162
24 May 21 Portnoy David Common Stock Option exercise Aquire M No No 2.9 32,184 93.33K 748,156
24 May 21 Portnoy David Common Stock Option exercise Aquire M No No 1.72 200,000 344K 715,972
24 May 21 Portnoy David Stock Option Common Stock Option exercise Dispose M No No 2.9 32,184 93.33K 67,816
24 May 21 Portnoy David Stock Option Common Stock Option exercise Dispose M No No 1.72 200,000 344K 0
24 May 21 Portnoy Mark L. Common Stock Option exercise Aquire M No No 2.9 32,184 93.33K 719,698
24 May 21 Portnoy Mark L. Common Stock Option exercise Aquire M No No 1.72 200,000 344K 687,514
24 May 21 Portnoy Mark L. Stock Option Common Stock Option exercise Dispose M No No 2.9 32,184 93.33K 67,816
24 May 21 Portnoy Mark L. Stock Option Common Stock Option exercise Dispose M No No 1.72 200,000 344K 0
21 May 21 Portnoy David Common Stock Buy Aquire P No No 8.46 1,000 8.46K 515,972

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

4.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 0 NEW
Opened positions 1 0 NEW
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 3.82M 0 NEW
Total shares 496.5K 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Iszo Capital 496.5K $3.82M NEW
Largest transactions
Shares Bought/sold Change
Iszo Capital 496.5K +496.5K NEW

Financial report summary

?
Competition
AthersysNatera
Management Discussion
  • Revenues.  Revenues for the three months ended February 28, 2021 were $6,860,617 compared to $7,620,774 for the same period in 2020, a 10% decrease.  The decrease in revenue was primarily attributable to a 9% decrease in processing and storage fees.
  • Processing and Storage Fees.  The decrease in processing and storage fee revenue is attributable to a decrease in the number of new domestic cord blood specimens offset by a 9% increase in recurring annual storage fee revenue.
  • Public Banking Revenue.  For the three months ended February 28, 2021, revenue from public banking was $83,986 compared to $154,079 for the three months ended February 29, 2020.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: administer, anniversary, autism, biopharmaceutical, buying, cerebral, core, cure, decline, declining, delay, Disorder, educational, equal, expertise, exploit, explore, extend, extended, field, fourth, Hedging, immunomodulatory, import, infusion, introducing, irrevocable, milestone, minimum, mitigate, mitigation, palsy, perpetual, Phase, proprietary, purpose, reached, recovery, regenerative, regulatory, rolling, smaller, sooner, Spectrum, speed, sublicense, technical, triad, trial, varying, volume, xxix, xxx
Removed: acquiring, affirmative, al, alleging, amounted, answer, behalf, bone, breached, Brotherson, CaresTM, Certification, Circuit, cloud, committee, complaint, comprehensive, computing, counterclaim, County, court, defendant, develop, Document, duly, evaluated, expanding, Gary, geographic, hosting, implementation, implementing, independent, installment, Instance, investigation, issue, jill, Judicial, jurisdictional, Label, lieu, Linkbase, lump, myeloablative, nonemployee, notice, opted, pending, personal, procedure, purportedly, reconstitution, record, registrant, relation, Schema, served, Simplifying, styled, sum, surrendered, Taxonomy, thereunto, unamortized, undersigned, violation, withheld, XBRL